Artifactual Sequence Chimera¶
An assay-generated nucleic-acid molecule joining contiguous sequence regions from distinct input templates into one product.
Core Idea¶
An artifactual sequence chimera is one nucleic-acid molecule synthesized during an assay whose contiguous sequence regions come from distinct input template molecules. The composite product was not an intact parent input. A later sequencing read may reveal it, but the read is evidence of the molecule rather than the object being defined. Reverse transcription and PCR can each produce such molecules by different assay routes.[1][2]
The word artifactual names its production history. A natural fusion transcript, a genomic rearrangement, and a deliberately assembled hybrid introduced as an input can also contain regions with different origins, but none becomes an artifact of this assay merely by looking composite. The two studies here support specific reverse-transcription and PCR realizations; they do not establish one universal joining mechanism, frequency, or detection algorithm.[1][2]
Structural Signature¶
- Distinct source templates. At least two input molecules supply sequence regions. Their different provenance is crucial, even when the templates have enough similarity to participate in an assay-specific joining route.[1][2]
- Laboratory synthesis workflow. The join arises while a new molecule is made in the experimental procedure. The cited cases use AMV reverse transcriptase and mixed-template PCR; neither enzyme is required for every possible case.[1][2]
- Single composite product. The result is one physical cDNA or amplified DNA molecule with contiguous regions traceable to different inputs, rather than a tube containing two separate parental molecules.[1][2]
- Provenance contrast. Known parents, controls, or other evidence establish that the composite was not already an intact input. A split-looking read alone is a candidate observation, not proof of when the join occurred; this evidential rule is an inference from the controlled parental design of the PCR study.[2]
Remove distinct input provenance or the one-product join, and the object is an ordinary copied parent or a mixture. Remove evidence that joining occurred during the assay, and the artifactual classification remains unproved, even if a sequence looks fused.[2]
What It Is Not¶
A mixture retains separate parent molecules. A naturally occurring fusion may already be present in the sample. A designed hybrid input can be copied faithfully without a new artifactual join. Organismal chimerism or mosaicism concerns distinct cellular lineages or genotypes within an organism, not one newly synthesized nucleic-acid product.[2]
A sequencing read or alignment is a measurement of a possible product, not itself proof that the laboratory made it. Likewise, an abundance-based filtering rule is one possible analytic tactic, not part of the identity. A reported chimeric rate depends on the assay and library design; the studies do not license one general rate.[2]
Scope of Application¶
The scope is experimental nucleic-acid synthesis when a composite molecule is attributed to more than one input template. Ouhammouch and Brody report chimeric cDNA from AMV reverse transcriptase switching between RNA templates in vitro. Omelina and colleagues use known plasmid parents to identify cross-parent PCR products in a barcode–region-of-interest assay. These are unlike workflows that instantiate the same product-level relation.[1][2]
The entry does not cover every biological use of chimera. Nor does it say that all reverse transcription or PCR creates such products. The 1992 homology and temperature findings belong to that tested AMV system; the 2019 rates and optimization results belong to its PCR designs.[1][2]
Clarity¶
A practical question is: what was one molecule before the assay, and what is one molecule after it? If a product joins a region from input A to a contiguous region from input B, while neither input contained that combination, it fits the product pattern. In the two-plasmid experiment, parental barcode–target pairs are known in advance; cross-parent pairings after amplification therefore provide a controlled contrast.[2]
The contrast is evidential, not a universal sequence-only signature. An apparent breakpoint in one read cannot by itself locate the joining event in laboratory time. The PCR study's parent markers and diagnostic controls support its conclusion; another proposed case would need comparable provenance evidence appropriate to its assay.[2]
Manages Complexity¶
Sequencing workflows can turn a synthesized molecule into a read and then into an inferred biological variant or barcode–target association. The chimera concept separates those stages: input templates, laboratory product, readout, and interpretation. In the MPRA study, cross-parent barcode–region-of-interest products could be mistaken for genuine library pairings if their origin is ignored.[2]
The separation matters because a downstream false association is a possible consequence, not a defining property. The same physical product remains artifactual when recognized and removed before interpretation. Conversely, a surprising read does not become an assay-generated chimera simply because its interpretation would be troublesome.[2]
Abstract Reasoning¶
Start with the known or reconstructed input molecules. Mark which regions of the proposed product correspond to each source, and ask whether the contiguous combination existed in any input. Then locate evidence that synthesis in the experiment generated the combination. Keep the molecule, the later read, and any biological inference as separate claims.[1][2]
This test rejects two easy mistakes. A sample containing both templates without a joined product is a mixture. A real pre-existing fusion can produce a composite-looking read without being a new assay artifact. The criterion can be met by different laboratory routes, as the reverse-transcription and PCR cases show; the shared logic is provenance across one synthesized molecule, not a universal enzyme step.[1][2]
Knowledge Transfer¶
The product-level test transfers between in-vitro cDNA synthesis and PCR amplification. In both, distinct input molecules supply regions of one new molecule; the experiments differ in templates, enzymes, and how their authors establish the join. The 1992 temperature behavior does not transfer as a law to PCR, nor do the 2019 diagnostic primers transfer automatically to cDNA work.[1][2]
A broader pattern of “parts from different sources presented as one” may be useful for reasoning elsewhere, but it omits this entry's nucleic-acid molecule and assay-production conditions. That portable skeleton is a future-Prime question, not proof of a present strict parent.[1][2]
Examples¶
In-vitro reverse-transcription product¶
Ouhammouch and Brody's original experiment reports that AMV reverse transcriptase switches between RNA templates during in-vitro cDNA synthesis and yields chimeric cDNA. The authors report dependence on template homology and temperature under their tested conditions. The published abstract supports this case; details beyond that abstract are not needed here.[1]
Mapped back: the RNA templates are the distinct source templates; AMV cDNA synthesis is the laboratory synthesis workflow; the chimeric cDNA is the single composite product; the experimentally reported template switch supplies the provenance contrast. The assay-specific temperature behavior is context, not a condition of every sequence chimera.[1]
Two-plasmid PCR product in an MPRA assay¶
Omelina and colleagues began with two plasmids bearing known barcode and region-of-interest pairings. After mixed-template amplification, their controlled diagnostic test detected cross-parent barcode–region-of-interest combinations absent from either original plasmid. They adjusted the test PCR to reduce false positives caused by that test itself.[2]
Mapped back: the two plasmids are the distinct source templates; mixed-template PCR is the laboratory synthesis workflow; each cross-parent amplified DNA molecule is the single composite product; the known parent pairings and controlled diagnostic procedure provide the provenance contrast. The study's particular chimeric rates and mitigation protocol are not universal values or requirements.[2]
Structural Tensions¶
The cited cases establish no intrinsic pair of competing objectives for an artifactual sequence chimera itself. Distinct-template joining defines the product; its existence does not require a choice between sensitivity and specificity, cost and accuracy, or any other fixed tradeoff. A claim that all such molecules embody one would add a condition unsupported by the reverse-transcription and PCR cases.[1][2]
There is a case-specific diagnostic hazard in Omelina's two-plasmid experiment: a test PCR intended to reveal cross-parent products can generate false cross-parent signal under some conditions. The authors compare diagnostic conditions and tune the test to avoid that problem. The useful question is whether the detection step was controlled before assigning the product to the earlier amplification. This is an experimental control issue for that case, not a defining tension of every chimera.[2]
Structural–Framed Character¶
Evaluative weight: artifact marks experimental origin relative to an intended measurement, not an intrinsic defect in the molecule. Human-practice dependence: assay setup and the chosen input set are needed to classify the product as made during the workflow. Institutional origin: sequencing and amplification laboratories study the category, but no particular institution is constitutive. Vocabulary travel: chimera also names cellular organisms, fusions, and designed hybrids; the label alone cannot carry the provenance claim across those uses. Import versus recognition: establish the molecular join and its timing from controls or parent evidence before importing the artifact label into an unexplained read.[1][2]
The portable skeleton is one output joining regions from distinct inputs while appearing to come from one source. Its literal extension outside nucleic-acid synthesis would need separate cross-domain cases and a future-Prime inquiry. Its character: a laboratory-framed molecular product category with a stable one-product provenance test, rather than a domain-free name for every composite thing.[1][2]
Structural Core vs. Domain Accent¶
The core relation is distinct input templates → assay synthesis → one joined molecule, supported by provenance contrast. The nucleic-acid substrate and experimental production history are the domain-bound mechanism. AMV reverse transcriptase versus PCR, RNA versus plasmid DNA, and temperature or cycle settings are accents of particular cases; removing all laboratory joining changes the named identity.[1][2]
This entry does not clear the Prime bar merely because “hybrid” or “composite” can describe many things. Its molecule-level origin condition has not been shown as a literal cross-domain identity. No direct live parent survived the typed-neighbor challenge, so the entry remains an approved root; any portable composite-provenance Prime is a future question, not an asserted ancestor.[1][2]
Instantiates / Related Primes¶
No strict direct edge is asserted in the current catalog. The reviewed placement is approved unparented root: it records the absence of a demonstrated all-instance direct parent, not a claim that the entry has no conceptual relations.[1][2]
The live Composition Prime is an aesthetic arrangement of parts into a cohesive whole; an unintended assay product need not instantiate that criterion. Sequence Homology concerns common ancestry of sequences, while chimera classification concerns the experimental history of one product. Mosaic Genetics is about cellular genotype populations. De Novo Transcriptome Assembly can encounter confusing reads but is a workflow, not the parent genus of all such molecules. Nucleic Acid Secondary Structure describes folding rather than cross-template origin. These are neighbors or contexts, not validated strict direct parents of both positive cases.[1][2]
Neighborhood in Abstraction Space¶
Artifactual Sequence Chimera sits in a sparse region of the domain-specific corpus (93rd percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.
Family — Unclustered & Miscellaneous (2551 abstractions)
Nearest neighbors
- Epitope mapping — 0.80
- Surveyor Nuclease Assay — 0.80
- DNA Replication — 0.79
- Expression Cloning — 0.78
- Artificial gene synthesis — 0.78
Computed from structural-signature embeddings · 2026-10-08
Not to Be Confused With¶
A mixed sample: two separate parental molecules with no one joined product. A natural fusion transcript or genomic rearrangement: a composite sequence that existed before the assay. A purpose-built hybrid input: a designed construct copied without a new accidental join. A chimeric sequencing read: a readout that may suggest a product but needs independent provenance. Cellular or organismal chimerism: distinct cells or lineages, not the single synthesized molecule defined here. One specific PCR detection rule: a method for certain assays, not the category's definition.[2]
References¶
[1] Mohamed Ouhammouch and Edward N. Brody, “Temperature-dependent template switching during in vitro cDNA synthesis by the AMV-reverse transcriptase,” Nucleic Acids Research 20, no. 20 (1992), pp. 5443–5450, abstract. https://pmc.ncbi.nlm.nih.gov/articles/PMC334354/ registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m ↩n ↩o ↩p ↩q ↩r ↩s ↩t
[2] Evgeniya S. Omelina et al., “Optimized PCR conditions minimizing the formation of chimeric DNA molecules from MPRA plasmid libraries,” BMC Genomics 20, supplement 7 (2019), article 536, Results, Figure 1b–d, Tables 1–2, and Discussion. https://pmc.ncbi.nlm.nih.gov/articles/PMC6620194/ registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m ↩n ↩o ↩p ↩q ↩r ↩s ↩t ↩u ↩v ↩w ↩x ↩y ↩z ↩27 ↩28 ↩29 ↩30